Callodine Specialty Income Fund (“CSIF“ or the “Fund”) is an unlisted closed-end management investment company that is structured as an interval fund. CSIF seeks to produce high current income by investing directly or indirectly in primarily a range of private corporate, real estate and alternative credit opportunities. At its core, the Fund’s strategic asset mix is designed to generate yield, optimize liquidity management and mitigate volatility.
Focused primarily on various middle market private credit investment strategies
Dedicated and highly experienced investment teams within each vertical
Seeks to blend income- oriented asset classes that may be less correlated with one another and provide different drivers of return
Interval fund structure offers access to private credit strategies that have historically been only available to institutional investors
Allocations, unless otherwise indicated, are based on the total portfolio and subject to change without notice. Data shown is for informational purposes only and not a recommendation to buy or sell any security.
YTD Return | 1 Year | 3 Year | 5 Year | 10 Year |
Inception
(01/01/2022)
|
---|---|---|---|---|---|
1.83% | 15.15% | 10.59% | -0.87% | --- | 1.39% |
Performance data quoted represents past performance and is no guarantee of future results. Investment return and principal value of an investment will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than their original cost. Current performance may be lower or higher than the performance data quoted. Performance shown is net of fees and reflects the reinvestment of dividends. Performance would have been lower without expense limitations currently in effect. Short term performance in particular is not a good indication of the fund’s future performance and an investment should not be made based solely on returns.
Callodine Specialty Income Fund is a multi-strategy interval fund that invests in both private credit and public, income-oriented assets through Callodine’s specialized investment teams. James Morrow & Gene Martin serve as Co-Portfolio Managers for the Fund and are supported by highly experienced investment professionals and their respective teams across asset-based lending, real estate lending, direct lending, life sciences finance, high yield debt, and yielding equity securities.
An investment in the Fund involves a high degree of risk, is considered speculative and illiquid, and is not suitable for all investors. No guarantee or representation is made that the Fund’s investment program, including, without limitation, its investment objectives, will be successful. Investors should consider the Fund as a supplement to an overall Investment program and should invest only if they are willing to undertake the risks involved, including the possible loss of all or a substantial portion of their investment. Below is a summary of some of the principal risks of investing in the Fund. For a more complete discussion of the risks of investing in the Fund, see " Principal Risk Factors" in the prospectus. Shareholders should consider carefully the following principal risks before investing in the Fund.
Before investing you should carefully consider the Fund's investment objectives, risks, charges and expenses. This and other information is in the prospectus, a copy of which may be obtained from the Fund at [insert toll-free number]. An investor should read the prospectus carefully before investing.
An investment in the Fund involves a high degree of risk, is considered speculative and illiquid, and is not suitable for all investors. There can be no assurance that the Fund’s investment objective will be achieved or that its investment program will be successful. Investors could lose some or all of their investment. No public market for Shares exists, and none is expected to develop in the future. Investors should generally not expect to be able to sell their Shares (other than through the limited repurchase process), regardless of how the Fund performs. Investors should consider the Fund as a supplement to an overall Investment program and should invest only if they are willing to undertake the risks involved, including risks that are inherent in securities investments generally as well as those risks that are specific to an investment in the Fund.
This information has been prepared by Callodine Capital Management, LP ("Callodine"), a registered investment adviser and adviser to the Callodine Specialty Income Fund (the "Fund"). Distribution Services, LLC (the "Distributor") acts as the principal underwriter of the Fund’s shares which is not affiliated with Callodine Capital Management, LP or any of their affiliates. Manning & Napier Investor Services, Inc. ("MNBD"), an affiliate of Callodine has a selling agreement in place to sell the Fund. This is neither an offer to sell nor a solicitation to purchase the securities described herein. Such an offering is made only by means of prospectus. Please read the prospectus prior to making any investment decisions and consider the risks, charges, expenses and other important information described therein. A copy of the prospectus must be made available to you in connection with any offering. Click here to view prospectus.
The information in this website may contain projections or other forward-looking statements regarding future events, targets, forecasts or expectations regarding the strategies described herein, and is only current as of the date indicated. There is no assurance that such events or targets will be achieved, and actual results may be significantly different from those shown here. The information set forth is subject to change without notice, including, without limitation, the terms of the Fund and any portfolio construction targets set forth herein, as well as market conditions and events. The views expressed reflect the current views of Callodine as of the date hereof and Callodine does not undertake to advise you of any changes in the views expressed herein.